CSS
ORMP icon

Cubist Systematic Strategies’s Oramed Pharmaceuticals ORMP Stock Holding History

Cubist Systematic Strategies’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-24,500
Closed -$295K – 4279
2022
Q4 		$295K Sell
24,500
-92,977
-79% -$723K ﹤0.01% 3368
2022
Q3 		$761K Buy
117,477
+46,756
+66% +$378K ﹤0.01% 2846
2022
Q2 		$324K Sell
70,721
-171,171
-71% -$915K ﹤0.01% 3379
2022
Q1 		$2.09M Buy
241,892
+191,316
+378% +$1.96M 0.02% 1436
2021
Q4 		$722K Buy
+50,576
New +$1.06M 0.01% 2167

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SIGI
Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cubist Systematic Strategies's ORMP Position: Q1 2023 in Review

Cubist Systematic Strategies sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 24,500 shares — an estimated $295K sold.

Cubist Systematic Strategies first reported a position in ORMP in Q4 2021 and held it in 5 quarters. The position peaked at $2.09M in Q1 2022. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

  • Cubist Systematic Strategies reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 24,500 Oramed Pharmaceuticals shares in Q1 2023, an estimated $295K.
  • Cubist Systematic Strategies first reported a position in Oramed Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • Cubist Systematic Strategies's Oramed Pharmaceuticals position peaked at $2.09M in Q1 2022.
  • 61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on Cubist Systematic Strategies's 13F filing for Q1 2023, filed 15 May 2023.